Biologics Quality Control Testing
ABOUT US
PathoQuest, a spin-out of Institut Pasteur Paris, is a genomics expert company offering a game-changing next-generation sequencing (NGS) approach for microbiology testing.
The NGS-based technology the company has developed is used for:
• The quality control (QC) testing of biologicals (e.g., ATMP, vaccines, antibodies), enabling rapid and robust analysis at a GMP level
PathoQuest’s technology leverages the company’s proprietary sample preparation protocols, which are applicable to several types of biological samples, proprietary internally-curated pathogen genome databases, and automated analysis pipelines.
LATEST NEWS
PathoQuest to Participate in CAACB Summer Workshop – Boston, USA| 20-21 July2022
High-throughput sequencing (HTSeq) is of high interest to biopharmaceutical
manufacturers as seen from recent survey results indicating that 81% of CAACB member companies are
currently using or exploring the use of HTSeq for viral safety and the remaining 19% expect to do so in the
future. Despite this significant interest, practical experience in the implementation of HTSeq is not widely
available. To address this gap, we are looking for presentations and case studies sharing practical experiences
with implementing HTSeq for a range of applications.
They talk about us: Staying abreast of regulations with NGS-based viral safety for faster, safer and more ethical lot release of vaccines.
In this European Pharmaceutical Review article, Sridhar Pennathur, Vice President, Analytical Development at Novavax, highlights the value of next generation sequencing in their vaccine production operations by answering key questions.
PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer
PathoQuest announced the appointment of Michael Mellor-Clark as company CCO. Michael Mellor-Clark has more than 20 years of commercial experience in biosafety testing services
Let’s Start Something New
Welcome to PathoQuest!
